Anthracyclines, e.g., doxorubicin or mitoxantrone, affect cancer cells by enhancing the cell surface expression of calreticulin (CRT) followed by the release of high-mobility group box 1 (HMGB1), ATP, annexin A1, and type I interferon from cancer cells [133,134,135,136]. This evidence concerns the gene HMGB1 and cancer.